Inventor · disambiguated record
David Michael Remick
Also filed as: REMICK DAVID M · REMICK DAVID MICHAEL
12 granted patents·8 pending applications·59 citations·filing 2001–2024
87Inventor score
Top patents by PatentIndex Score
20 records- 0194US11834435B2SSTR4 agonist saltsLILLY CO ELI·Filed 2022·Granted Dec 5, 2023·3 cites·19 claims
- 0285US7320994B2Triazole derivatives as tachykinin receptor antagonistsLILLY CO ELI·Filed 2003·Granted Jan 22, 2008·28 cites·34 claims
- 0384US6730792B2β3 adrenergic agonistsLILLY CO ELI·Filed 2001·Granted May 4, 2004·21 cites·17 claims
- 0481US11926634B2Processes for the preparation of selective estrogen receptor degradersLILLY CO ELI·Filed 2023·Granted Mar 12, 2024·1 cites·20 claims
- 0580US12102610B2Treprostinil saltLILLY CO ELI·Filed 2019·Granted Oct 1, 2024·1 cites·19 claims
- 0680US7691827B2Amide prodrug of gemcitabine, compositions and use thereofLILLY CO ELI·Filed 2005·Granted Apr 6, 2010·5 cites·6 claims
- 0780US2024308975A1Polymorphs of an ssao inhibitorLILLY CO ELI·Filed 2024·Application pending·0 cites
- 0878US12486249B2SSTR4 agonist saltsLILLY CO ELI·Filed 2023·Granted Dec 2, 2025·0 cites·11 claims
- 0970US11820754B2Polymorphs of an SSAO inhibitorLILLY CO ELI·Filed 2021·Granted Nov 21, 2023·0 cites·18 claims
- 1068US12365682B2Process to make GLP1 RA and intermediates thereforLILLY CO ELI·Filed 2024·Granted Jul 22, 2025·0 cites·20 claims
- 1167US2024307349A1Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereofLILLY CO ELI·Filed 2024·Application pending·0 cites
- 1265US10787460B2(E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7LILLY CO ELI·Filed 2019·Granted Sep 29, 2020·0 cites·17 claims
- 1363US2021032257A1(e)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting cdk7LILLY CO ELI·Filed 2020·Application pending·0 cites
- 1458US2024199629A1Processes for the preparation of selective estrogen receptor degradersLILLY CO ELI·Filed 2024·Application pending·0 cites
- 1551US2022289716A1Crystalline forms of a cd73 inhibitorLILLY CO ELI·Filed 2020·Application pending·0 cites
- 1650US2004242633A1Beta3 adrenergic agonistsFiled 2004·Application pending·0 cites
- 1748US2022153750A1Salts of 5,6-dihydro-4h-thieno[2,3-c]pyrrol-4-one compound as erk inhibitorsLILLY CO ELI·Filed 2020·Application pending·0 cites
- 1842US10011610B2Selective BACE1 inhibitorsLILLY CO ELI·Filed 2016·Granted Jul 3, 2018·0 cites·20 claims
- 1942US8299060B2Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acidCHEN XINCHAO·Filed 2010·Granted Oct 30, 2012·0 cites·21 claims
- 2041US2006167051A1Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochlorideREMICK DAVID M·Filed 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Michael Remick files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →